Haben 23 Mio Shares am Markt, laut otcbb. WKN: A0CAB7 Kurs: 0,24 USD Symbol: IRBOE/IRBO
Ein Biowert für die Watchliste, denke der wird noch kräftig fallen (0,03-0,01?). Halt ein Neustart!(Split (06.04.04) 1:2, Kurs verwässert!)
isht.comdirect.de/charts/...ors=0x000000&sSym=IRBO.NAP&hcmask=
IRBO IR BIOSCIENCES HLDNG IN
IRBOE IR BIOSCIENCES HOLDINGS, INC
--------------------------------------------------
IR BioSciences Holdings, Inc. - SEC Filing Status
WEDNESDAY, APRIL 21, 2004 10:31 AM
SCOTTSDALE, Ariz., Apr 21, 2004 /PRNewswire-FirstCall via COMTEX/ -- IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO)has recently received an "e" on its ticker symbol due to audit filing delays. This "e" is a representation of the delay in filing and its purpose is to notify shareholders that a company has been delayed in meeting the filing date.
Certain factors delayed the company in completing the audit on time. Nevertheless, the company presently is working on it and expects to complete it shortly. "We continuously focus on all aspects of our business and apologize for these delays. We are working with our auditors and remain committed to meeting all requirements for filing. We expect the removal of the "e" in the shortest order possible," says Michael Wilhelm.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc. is a biotechnology company engaged in the research and development of applications utilizing modified Substance P, a naturally occurring immunomodulator. Derived from homeostatic substance P, the company has named their proprietary compound "Homspera." The Company's initial focus is on the continuing development of Homspera for various applications for use in improving pulmonary function and stimulating the human immune system. For more information, please visit the Company's website at www.immuneregen.com.
About Homspera
ImmuneRegen's patents and continued substance P research are derived from discoveries made during research funded by the Air Force Office of Scientific Research in the early 1990s. During this research, Dr. Witten and his associates observed that the exposure of animals to jet fuels resulted in pathological changes in the lung and immune systems of those exposed. It was also observed that such exposure resulted in depletion of substance P from the lungs of the animals. These studies further showed that the administration of substance P may help prevent and reverse the effects of jet fuel exposure in the lungs, as well as protect and regenerate the immune system. The immune findings led to early research on the treatment of exposure to acute radiation and on the possible reversal of lung damage caused by ARDS and cigarette smoke.
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research collaborations, clinical trials and product development programs, the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Company's SEC filings.
SOURCE IR BioSciences Holdings, Inc.
Ein Biowert für die Watchliste, denke der wird noch kräftig fallen (0,03-0,01?). Halt ein Neustart!(Split (06.04.04) 1:2, Kurs verwässert!)
isht.comdirect.de/charts/...ors=0x000000&sSym=IRBO.NAP&hcmask=
IRBO IR BIOSCIENCES HLDNG IN
IRBOE IR BIOSCIENCES HOLDINGS, INC
--------------------------------------------------
IR BioSciences Holdings, Inc. - SEC Filing Status
WEDNESDAY, APRIL 21, 2004 10:31 AM
SCOTTSDALE, Ariz., Apr 21, 2004 /PRNewswire-FirstCall via COMTEX/ -- IR BioSciences Holdings, Inc. (OTC Bulletin Board: IRBO)has recently received an "e" on its ticker symbol due to audit filing delays. This "e" is a representation of the delay in filing and its purpose is to notify shareholders that a company has been delayed in meeting the filing date.
Certain factors delayed the company in completing the audit on time. Nevertheless, the company presently is working on it and expects to complete it shortly. "We continuously focus on all aspects of our business and apologize for these delays. We are working with our auditors and remain committed to meeting all requirements for filing. We expect the removal of the "e" in the shortest order possible," says Michael Wilhelm.
About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc. is a biotechnology company engaged in the research and development of applications utilizing modified Substance P, a naturally occurring immunomodulator. Derived from homeostatic substance P, the company has named their proprietary compound "Homspera." The Company's initial focus is on the continuing development of Homspera for various applications for use in improving pulmonary function and stimulating the human immune system. For more information, please visit the Company's website at www.immuneregen.com.
About Homspera
ImmuneRegen's patents and continued substance P research are derived from discoveries made during research funded by the Air Force Office of Scientific Research in the early 1990s. During this research, Dr. Witten and his associates observed that the exposure of animals to jet fuels resulted in pathological changes in the lung and immune systems of those exposed. It was also observed that such exposure resulted in depletion of substance P from the lungs of the animals. These studies further showed that the administration of substance P may help prevent and reverse the effects of jet fuel exposure in the lungs, as well as protect and regenerate the immune system. The immune findings led to early research on the treatment of exposure to acute radiation and on the possible reversal of lung damage caused by ARDS and cigarette smoke.
Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research collaborations, clinical trials and product development programs, the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Company's SEC filings.
SOURCE IR BioSciences Holdings, Inc.
